Hemostemix Inc (HEM) - Total Assets
Based on the latest financial reports, Hemostemix Inc (HEM) holds total assets worth CA$1.34 Million CAD (≈ $968.53K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hemostemix Inc - Total Assets Trend (2013–2024)
This chart illustrates how Hemostemix Inc's total assets have evolved over time, based on quarterly financial data. Also see HEM market cap for the company's overall valuation and market capitalisation.
Hemostemix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Hemostemix Inc's total assets of CA$1.34 Million consist of 100.0% current assets and 0.0% non-current assets. Review HEM total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 71.2% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$1.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Hemostemix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See HEM live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hemostemix Inc's current assets represent 100.0% of total assets in 2024, an increase from 76.1% in 2013.
- Cash Position: Cash and equivalents constituted 71.2% of total assets in 2024, up from 43.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 0.0% of total assets.
Hemostemix Inc Competitors by Total Assets
Key competitors of Hemostemix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Hemostemix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 0.04 | 0.68 |
| Quick Ratio | 1.54 | 0.04 | 1.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$470.35K | CA$-3.41 Million | CA$-1.10 Million |
Hemostemix Inc - Advanced Valuation Insights
This section examines the relationship between Hemostemix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.76 |
| Latest Market Cap to Assets Ratio | 9.62 |
| Asset Growth Rate (YoY) | 216.1% |
| Total Assets | CA$991.86K |
| Market Capitalization | $9.54 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Hemostemix Inc's assets at a significant premium (9.62x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Hemostemix Inc's assets grew by 216.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hemostemix Inc (2013–2024)
The table below shows the annual total assets of Hemostemix Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$991.86K ≈ $717.50K |
+216.12% |
| 2023-12-31 | CA$313.76K ≈ $226.97K |
-32.57% |
| 2022-12-31 | CA$465.35K ≈ $336.62K |
-17.35% |
| 2021-12-31 | CA$563.05K ≈ $407.30K |
-75.76% |
| 2020-12-31 | CA$2.32 Million ≈ $1.68 Million |
+2127.73% |
| 2019-12-31 | CA$104.28K ≈ $75.43K |
-93.73% |
| 2018-12-31 | CA$1.66 Million ≈ $1.20 Million |
-68.65% |
| 2017-12-31 | CA$5.30 Million ≈ $3.84 Million |
+2234.76% |
| 2016-12-31 | CA$227.11K ≈ $164.29K |
-71.50% |
| 2015-12-31 | CA$796.81K ≈ $576.40K |
-79.78% |
| 2014-12-31 | CA$3.94 Million ≈ $2.85 Million |
+382.51% |
| 2013-12-31 | CA$816.85K ≈ $590.90K |
-- |
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more